Close Menu
November 18, 2019
Sponsored by
Mission Bio

Simultaneous Single-Cell DNA and Protein Sequencing in AML Samples

Genome Webinar

This webinar will outline the results of a study that performed integrative single-cell genome and cell surface protein expression profiling of adult acute myeloid leukemia (AML) cases. 

Genomic studies of AML have identified mutations with varying allele frequencies, which suggests a step-wise acquisition of mutation in leukemogenesis. Bulk sequencing can provide prognostic information, but it cannot delineate clonal architecture at the single-cell level. Additionally, the complementation of immunophenotype with corresponding mutational analysis could elucidate important dynamics in the leukemic cell population, but has yet to be assayed in parallel.

In this webinar, Linde Miles of Memorial Sloan Kettering Cancer Center will share data from the study demonstrating that simultaneous single-cell sequencing of DNA and protein can identify populations of stem/progenitor cells with distinct clonal/mutational and protein expression profiles. She will also discuss how the method identified trends in protein expression when comparing multiple samples with similar mutations. 

Attendees of this webinar will learn about:

  • New DNA+protein capability from Mission Bio for simultaneous, targeted, single-cell DNA and protein sequencing
  • A novel 6-antibody cocktail in combination with a single-cell targeted DNA custom AML panel 
  • The relationship between mutational profile and cell surface protein expression in AML samples from six clinical research samples 
Sponsored by
Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.

Mar
11
Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
25
Sponsored by
Foundation Medicine

In this session, the fourth in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling identified no clear molecular markers to help guide personalized therapy.